«The data presented at AACR provide important new models and mechanistic insights that inform our planned development efforts to evaluate the ability of microbiome therapy to
augment immune checkpoint inhibitors,» said David Cook, Ph.D., Chief Scientific Officer and Executive Vice President of Research at Seres.